TY - JOUR
T1 - Bone marrow-derived macrophages converted into cancer-associated fibroblast-like cells promote pancreatic cancer progression
AU - Iwamoto, Chika
AU - Ohuchida, Kenoki
AU - Shinkawa, Tomohiko
AU - Okuda, Sho
AU - Otsubo, Yoshiki
AU - Okumura, Takashi
AU - Sagara, Akiko
AU - Koikawa, Kazuhiro
AU - Ando, Yohei
AU - Shindo, Koji
AU - Ikenaga, Naoki
AU - Nakata, Kohei
AU - Moriyama, Taiki
AU - Miyasaka, Yoshihiro
AU - Takao, Ohtsuka
AU - Eto, Masatoshi
AU - Akashi, Koichi
AU - Nakamura, Masafumi
N1 - Funding Information:
This work was supported in part by a JSPS KAKENHI Grant Numbers JP17H04284 (to K. O.), JP19H03732 (to M. N.), JP19K22663 (to M. N.), JP19K22664 (to K. O.), JP18K16366 (to C. I.), and grant from Pancreas Research Foundation of Japan (to C. I.) and the Clinical Research Promotion Foundation (to C. I.).
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/8/1
Y1 - 2021/8/1
N2 - Pancreatic ductal adenocarcinoma (PDAC) is characterized by a desmoplastic reaction caused by cancer-associated fibroblasts (CAFs), which provokes treatment resistance. CAFs are newly proposed to be heterogeneous populations with different functions within the PDAC microenvironment. The most direct sources of CAFs are resident tissue fibroblasts and mesenchymal stem cells, however, the origins and functions of CAF subtypes remain unclear. Here, we established allogeneic bone marrow (BM) transplantation models using spontaneous PDAC mice, and then investigated what subtype cells derived from BM modulate the tumor microenvironment and affect the behavior of pancreatic cancer cells (PCCs). BM-derived multilineage hematopoietic cells were engrafted in recipient pancreas, and accumulated at the invasive front and central lesion of PDAC. We identified BM macrophages-derived CAFs in tumors. BM-derived macrophages treated with PCC-conditioned media expressed CAF markers. BM-derived macrophages led the local invasion of PCCs in vitro and enhanced the tumor invasive growth in vivo. Our data suggest that BM-derived cells are recruited to the pancreas during carcinogenesis and that the specific subpopulation of BM-derived macrophages partially converted into CAF-like cells, acted as leading cells, and facilitated pancreatic cancer progression. The control of the conversion of BM-derived macrophages into CAF-like cells may be a novel therapeutic strategy to suppress tumor growth.
AB - Pancreatic ductal adenocarcinoma (PDAC) is characterized by a desmoplastic reaction caused by cancer-associated fibroblasts (CAFs), which provokes treatment resistance. CAFs are newly proposed to be heterogeneous populations with different functions within the PDAC microenvironment. The most direct sources of CAFs are resident tissue fibroblasts and mesenchymal stem cells, however, the origins and functions of CAF subtypes remain unclear. Here, we established allogeneic bone marrow (BM) transplantation models using spontaneous PDAC mice, and then investigated what subtype cells derived from BM modulate the tumor microenvironment and affect the behavior of pancreatic cancer cells (PCCs). BM-derived multilineage hematopoietic cells were engrafted in recipient pancreas, and accumulated at the invasive front and central lesion of PDAC. We identified BM macrophages-derived CAFs in tumors. BM-derived macrophages treated with PCC-conditioned media expressed CAF markers. BM-derived macrophages led the local invasion of PCCs in vitro and enhanced the tumor invasive growth in vivo. Our data suggest that BM-derived cells are recruited to the pancreas during carcinogenesis and that the specific subpopulation of BM-derived macrophages partially converted into CAF-like cells, acted as leading cells, and facilitated pancreatic cancer progression. The control of the conversion of BM-derived macrophages into CAF-like cells may be a novel therapeutic strategy to suppress tumor growth.
UR - http://www.scopus.com/inward/record.url?scp=85105483243&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105483243&partnerID=8YFLogxK
U2 - 10.1016/j.canlet.2021.04.013
DO - 10.1016/j.canlet.2021.04.013
M3 - Article
C2 - 33961925
AN - SCOPUS:85105483243
SN - 0304-3835
VL - 512
SP - 15
EP - 27
JO - Cancer Letters
JF - Cancer Letters
ER -